

Issue and repurchase of series C shares for share saving program

Pursuant to the authorization granted by the annual general meeting on 19 May 2022, the board of directors of BONESUPPORT HOLDING AB ("BONESUPPORT") has resolved to issue and immediately thereafter repurchase 639,572 series C shares. The shares are issued and repurchased to secure delivery of shares for the share saving program LTI 2021, which was adopted by the 2021 annual general meeting and thereby replaces the share swap resolved by the same annual general meeting.

Pursuant to the authorization granted by the annual general meeting on 19 May 2022, the board of directors of BONESUPPORT has resolved to issue 639,572 series C shares to Skandinaviska Enskilda Banken AB. The subscription price per share amounts to SEK 0.625, which corresponds to the quota value of the shares. Furthermore, the board of directors has resolved to immediately repurchase all 639,572 series C shares from Skandinaviska Enskilda Banken AB at a price corresponding to the subscription price.

The purpose of the issue and the repurchase of series C shares is to, when the series C shares have been converted to ordinary shares, ensure delivery of performance shares to employees within the BONESUPPORT group who are participating in the share saving program LTI 2021, which was adopted by the annual general meeting on 20 May 2021, which means that the issue of series C shares replaces the share swap resolved by the same annual general meeting. Allotment of performance shares shall take place within 30 days from the publication of the year-end report for the financial year 2023.

Since previously, BONESUPPORT holds 1,002,866 own series C shares. The series C shares carry one-tenth of a vote per share and do not entitle to dividends.

This information was submitted for publication, through the agency of the contact persons set out below, at 14:15 CET on 9 December 2022.

For more information contact:

BONESUPPORT Holding AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com

Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se

Press Release
09 December 2022 14:15:00 CET



About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform **CERAMENT**. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 213 million in 2021. Please visit www.bonesupport.com for more information.

BONESUPPORT and CERAMENT are **registered trademarks** of BONESUPPORT AB.

Attachments

[Issue and repurchase of series C shares for share saving program](#)